8-K: Carlsmed Reports Strong Q3 2025, Raises Full-Year Guidance

Carlsmed, Inc. announced robust third-quarter 2025 financial results, including 98% year-over-year revenue growth, and raised its full-year revenue guidance.

Summary

• Third quarter 2025 revenue reached $13.1 million, marking a 98% increase year-over-year.
• Gross margin expanded to 75.9% for Q3 2025, up from 72.8% in Q3 2024.
• Net loss for Q3 2025 was ($8.5) million, compared to ($7.8) million in Q3 2024.
• Adjusted EBITDA loss for Q3 2025 was ($8.2) million, compared to ($7.7) million in Q3 2024.
• Full-year 2025 revenue guidance was raised to a range of $49.0 million to $50.0 million, representing 80% to 84% growth over 2024.
• Surgeon users increased by more than 70% year-over-year.
• Lead times for aprevo interbody implants were reduced to within 8 business days.
• CMS New Technology Add-On Payment (NTAP) for aprevo cervical procedures went into effect on October 1, 2025, with commercial launch expected in early 2026.
• Clinical data presented showed a 75% reduction in revision surgery at a two-year time point for aprevo versus a patient-matched cohort.
• An amendment to the existing debt facility was executed in October, increasing maximum availability to $50 million and extending the maturity date and interest-only payment period.
• Jennifer Kamocsay was appointed as Chief Legal Officer and Secretary.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, expanded gross margins, and raised full-year guidance, indicating robust operational performance and market traction. Key strategic milestones, such as NTAP reimbursement for cervical procedures and positive clinical data, further enhance the positive outlook. While net losses increased, this is typical for a high-growth medical technology company investing in future expansion. The debt facility amendment also provides financial stability for continued growth.

Positives

• Achieved 98% year-over-year revenue growth in Q3 2025, reaching $13.1 million.
• Expanded gross margins to 75.9% in Q3 2025, up from 72.8% in Q3 2024.
• Increased surgeon users by over 70% year-over-year.
• Reduced lead times for aprevo interbody implants to 8 business days (from 20 business days in Q3 2024).
• Secured CMS New Technology Add-On Payment (NTAP) for aprevo cervical procedures, effective October 1, 2025.
• Successfully completed over 50 cervical aprevo procedures as part of the clinical evaluation program.
• Clinical data demonstrated a 75% reduction in revision surgery at a two-year time point for aprevo versus a patient-matched cohort.
• Raised full-year 2025 revenue guidance to $49.0 $50.0 million, representing 80% to 84% growth over 2024, an increase from prior guidance.
• Amended the debt facility, increasing maximum availability to $50 million and extending the maturity and interest-only payment period, enhancing financial flexibility.
• Maintained a strong cash position with $115.5 million in cash and equivalents as of September 30, 2025.

Negatives

• Net loss increased to ($8.5) million in Q3 2025 from ($7.8) million in Q3 2024.
• Adjusted EBITDA loss increased to ($8.2) million in Q3 2025 from ($7.7) million in Q3 2024.
• Operating expenses significantly increased to $19.0 million in Q3 2025 from $12.6 million in Q3 2024, driven by increases in research and development, sales and marketing, and general and administrative expenses.

Risks

• Forward-looking statements are subject to various important factors, including those set forth under the caption Risk Factors in the company's Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission, which could cause actual results to differ materially.

Future Outlook

Carlsmed expects full-year 2025 revenue to be in the range of $49.0 million to $50.0 million, an increase from previous guidance, representing 80% to 84% growth over 2024. The company also anticipates commercially launching its aprevo cervical spine platform in the United States in early 2026, following successful clinical evaluation and securing NTAP reimbursement.

Management Comments

• "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and speed at which we are scaling while maintaining operational excellence."
• "With NTAP reimbursement for cervical procedures secured and more than 50 patients treated in our clinical evaluation, we are tracking toward launching our cervical spine platform early next year to bring our transformative digital surgery approach to an even broader patient population."

Industry Context

Carlsmed operates in the highly innovative medical technology sector, specializing in AI-enabled personalized spine surgery solutions. The company's reported 98% year-over-year revenue growth and expanded gross margins indicate strong market penetration and efficient scaling within a competitive industry. The securing of NTAP reimbursement for cervical procedures is a significant regulatory and commercial milestone, aligning with broader industry trends towards personalized medicine and digital health integration in surgical procedures, which could accelerate adoption and market share gains for its specialized technology.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks.
• The 98% year-over-year revenue growth is exceptionally high for the medical technology sector, particularly for a company scaling its operations, suggesting strong market penetration and demand for its innovative solutions, likely outperforming many established industry players.
• A gross margin of 75.9% is robust and generally indicative of a strong competitive position and efficient production within the medical device industry, often exceeding the average for many manufacturing sectors.
• The reported 75% reduction in revision surgery at a two-year time point for aprevo, compared to a patient-matched cohort, represents a significant clinical outcome that, if widely validated, could set a new standard for efficacy in spine surgery and differentiate Carlsmed from competitors using traditional methods.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, raised guidance, expanded margins, and operational achievements, potentially leading to increased share value. The increased losses are a factor but are offset by growth prospects.
• Customers (Surgeons/Hospitals): Positive impact from reduced lead times for implants and the upcoming commercial launch of cervical procedures, enhancing product availability and treatment options.
• Patients: Positive impact from the availability of AI-enabled personalized spine surgery solutions, especially with clinical data showing a 75% reduction in revision surgery.
• Employees: Positive outlook due to company growth and expansion, potentially leading to more opportunities and job security.
• Creditors: Positive impact from the amendment to the debt facility, which increases availability and extends payment terms, indicating financial flexibility and confidence in the company's future.

Next Steps

• Commercially launch the aprevo cervical spine platform in the United States in early 2026.
• Continue scaling operations and maintaining operational excellence in manufacturing and delivery.
• Further clinical evaluation and data presentation for aprevo technology to support market adoption and expand indications.

Key Dates

Recommendation

Carlsmed demonstrates exceptional growth with a 98% year-over-year revenue increase and a significant raise in full-year guidance, indicating strong market adoption and operational execution. Gross margins are robust, and key strategic milestones like NTAP reimbursement for cervical procedures and positive clinical data for revision surgery reduction are highly favorable. While the company is still operating at a net loss, this is expected for a high-growth medical technology firm investing heavily in scaling and R&D. The increased debt facility provides additional capital for continued expansion. These factors collectively point to strong future potential and make it an attractive investment.

Keywords

Carlsmed, medical technology, AI-enabled surgery, personalized spine surgery, aprevo, interbody implants, cervical procedures, NTAP, financial results, revenue growth, gross margin, debt facility, corporate governance